-+ 0.00%
-+ 0.00%
-+ 0.00%

AbelZeta wins FDA IND clearance for C-CAR039 in relapsed, refractory large B-cell lymphoma

PUBT·08/17/2026 00:47:19
Listen to the news
AbelZeta wins FDA IND clearance for C-CAR039 in relapsed, refractory large B-cell lymphoma
  • AbelZeta received FDA clearance for an IND for C-CAR039 (Prizlon-cel) in relapsed or refractory large B-cell lymphoma.
  • The company plans US trials in third-line or later patients previously treated with CAR-T, also second-line CAR-T-naive patients.
  • AbelZeta regained global rights to C-CAR039 in July 2026, covering development, manufacturing, commercialization, out-licensing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abelzeta Inc. published the original content used to generate this news brief on August 16, 2026, and is solely responsible for the information contained therein.